Zeyang Ding

2.7k total citations · 1 hit paper
92 papers, 1.8k citations indexed

About

Zeyang Ding is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Zeyang Ding has authored 92 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 20 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Zeyang Ding's work include RNA modifications and cancer (14 papers), TGF-β signaling in diseases (10 papers) and Liver physiology and pathology (8 papers). Zeyang Ding is often cited by papers focused on RNA modifications and cancer (14 papers), TGF-β signaling in diseases (10 papers) and Liver physiology and pathology (8 papers). Zeyang Ding collaborates with scholars based in China, United States and Hong Kong. Zeyang Ding's co-authors include Bixiang Zhang, Xiaoping Chen, Huifang Liang, Ganxun Li, Weixun Chen, Guan-nan Jin, Zhao Huang, Jia Song, Peng Zhu and Wanguang Zhang and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Zeyang Ding

83 papers receiving 1.8k citations

Hit Papers

Cancer stem cells and niches: challenges in immunotherapy... 2025 2026 2025 10 20 30

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zeyang Ding China 28 853 474 429 279 248 92 1.8k
Vasiliki Gkretsi Cyprus 24 722 0.8× 262 0.6× 498 1.2× 133 0.5× 224 0.9× 57 1.9k
Laura Porretti Italy 27 840 1.0× 284 0.6× 219 0.5× 216 0.8× 347 1.4× 72 2.1k
Ze Zhang China 21 700 0.8× 322 0.7× 325 0.8× 179 0.6× 192 0.8× 65 1.4k
Konduru S. Sastry United States 21 583 0.7× 199 0.4× 355 0.8× 203 0.7× 239 1.0× 34 1.9k
Yong Fu China 21 713 0.8× 425 0.9× 200 0.5× 160 0.6× 247 1.0× 94 1.4k
Anna Sebestyén Hungary 22 1.1k 1.3× 518 1.1× 464 1.1× 139 0.5× 126 0.5× 103 1.9k
Loı̈c Vincent France 20 811 1.0× 430 0.9× 423 1.0× 132 0.5× 247 1.0× 62 1.8k
Xiaoping Jiang China 25 640 0.8× 177 0.4× 677 1.6× 458 1.6× 229 0.9× 54 2.2k
Qihui Zhai United States 23 596 0.7× 272 0.6× 441 1.0× 517 1.9× 401 1.6× 69 1.6k
Zhifeng Gu China 22 683 0.8× 280 0.6× 187 0.4× 93 0.3× 234 0.9× 86 1.7k

Countries citing papers authored by Zeyang Ding

Since Specialization
Citations

This map shows the geographic impact of Zeyang Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeyang Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeyang Ding more than expected).

Fields of papers citing papers by Zeyang Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeyang Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeyang Ding. The network helps show where Zeyang Ding may publish in the future.

Co-authorship network of co-authors of Zeyang Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Zeyang Ding. A scholar is included among the top collaborators of Zeyang Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeyang Ding. Zeyang Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhu, Jinghan, Yixiao Xiong, Yuxin Zhang, et al.. (2025). Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma. Cancer Communications. 45(8). 1038–1071. 2 indexed citations
2.
Ding, Zeyang, Zonghang Liu, Ying Peng, et al.. (2025). Photo-induced hydrous organic aggregates for photoactivatable luminescence. Nature Communications. 16(1). 5594–5594. 1 indexed citations
3.
Ding, Zeyang, Hanwen Liu, Haoran Wang, et al.. (2025). Through-space conjugation engineering in methylated tetraphenylethene derivatives. Chemical Communications. 61(92). 18100–18103.
4.
Zhu, Chang, Huifang Liang, Zeyang Ding, et al.. (2025). Exon Skipping of Ste20- Like Kinase Enhances Glycolysis and Tumor Progression by Activating Enolase 1–Mediated Phosphoenolpyruvate Production. Cancer Research. 85(20). 3930–3948. 1 indexed citations
5.
Peng, Ying, Zeyang Ding, Huilin Xie, et al.. (2025). Neuronal Tracing and Visualization of Nerve Injury by a Membrane-Anchoring Aggregation-Induced Emission Probe. ACS Nano. 19(1). 1070–1079. 1 indexed citations
6.
Gao, Fei, Dan Liu, Zeyang Ding, et al.. (2025). In-Solution Intramolecular Through-Space Conjugations of Sterically Constrained Tetranaphthylethane. CCS Chemistry. 8(1). 234–245. 1 indexed citations
7.
Siddiqui, Junaid Ali, Ruidong Fan, Yanjiang Liu, et al.. (2025). The larval gut of Spodoptera frugiperda harbours culturable bacteria with metabolic versatility after insecticide exposure. Insect Molecular Biology. 34(3). 452–469.
8.
Li, Ganxun, Tongtong Liu, Guan-nan Jin, et al.. (2024). GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers. Cancer Gene Therapy. 31(4). 586–598. 2 indexed citations
9.
He, Yi, Ganxun Li, Zeyu Chen, et al.. (2024). Actin like 6A is a prognostic biomarker and associated with immune cell infiltration in cancers. Discover Oncology. 15(1).
10.
Fan, Yu, et al.. (2024). Diversity and Geographic Distribution Patterns of Wild Magnoliaceae Species in China. Sustainability. 16(21). 9448–9448. 1 indexed citations
11.
Peng, Ying, Mingwang Yang, Huilin Xie, et al.. (2024). Mitochondria-Targeting AIEgens as Pyroptosis Inducers for Boosting Type-I Photodynamic Therapy of Tongue Squamous Cell Carcinoma. ACS Nano. 19 indexed citations
13.
Xu, Lei, Qiumeng Liu, Hui Li, et al.. (2024). Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation. Cancer Communications. 44(9). 1018–1041. 20 indexed citations
14.
Xiao, Chen, Jiayuan Li, Xing Wang, et al.. (2023). Hydroxyethyl starch stabilized copper-diethyldithiocarbamate nanocrystals for cancer therapy. Journal of Controlled Release. 356. 288–305. 23 indexed citations
15.
Wei, Yi, Tuying Yong, Wenlong Jia, et al.. (2023). Bone Lesion‐Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5‐Targeting miR‐3190‐5p. Advanced Science. 10(17). e2207080–e2207080. 19 indexed citations
16.
Li, Ganxun, et al.. (2023). IMOPAC: A web server for interactive multiomics and pharmacological analyses of patient-derived cancer cell lines. Computational and Structural Biotechnology Journal. 21. 3705–3714. 1 indexed citations
17.
Huang, Zhao, Jingyuan Wen, Jingjing Yu, et al.. (2020). MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner. Journal of Experimental & Clinical Cancer Research. 39(1). 150–150. 28 indexed citations
18.
19.
Gong, Qiong, Peng Zhu, Binhao Zhang, et al.. (2018). Safety and efficacy of n-3 fatty acid-based parenteral nutrition in patients with obstructive jaundice: a propensity-matched study. European Journal of Clinical Nutrition. 72(8). 1159–1166. 7 indexed citations
20.
Chen, Lin, Wei Zhang, Huifang Liang, et al.. (2014). Activin A induces growth arrest through a SMAD- dependent pathway in hepatic progenitor cells. Cell Communication and Signaling. 12(1). 18–18. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026